Averica and Dalton Announce Analytical Chemistry Services Agreement

Share Article

Averica Discovery Services Inc., an analytical development Contract Research Organization (CRO) based in the Greater Boston area, and Dalton Pharma Services, a contract provider of integrated chemistry, drug development, and manufacturing services located in Toronto, today announce a preferred provider agreement involving advanced analytical services.

30 years Dalton logo
“We are very pleased to have established and qualified Averica as a trusted partner, Averica and Dalton are premium contract vendors known for a culture of excellence and the ability to deal with technically challenging compounds.”

Averica Discovery Services Inc., an analytical development Contract Research Organization (CRO) based in the Greater Boston area, and Dalton Pharma Services, a contract provider of integrated chemistry, drug development, and manufacturing services located in Toronto, today announce a preferred provider agreement involving advanced analytical services.

The agreement leverages the strengths of both companies in order to enhance client pharmaceutical development programs. Averica provides specialized expertise in impurity isolation, small molecule analysis and purification. Dalton is a full service contract provider with a strong focus on Active Pharmaceutical Ingredient (API) development and cGMP manufacturing. Averica’s capabilities will expand Dalton’s capacity and allow faster validation of assay, impurities, and release testing methods. The key expertise of Averica in impurity isolation can also improve timelines for Dalton’s clinical and commercial cGMP synthesis.

“We are very pleased to have established and qualified Averica as a trusted partner,” said Peter Pekos, CEO and President of Dalton Pharma Services. “Averica and Dalton are premium contract vendors known for a culture of excellence and the ability to deal with technically challenging compounds.”

Jeffrey Kiplinger, Ph.D., President of Averica added, “This agreement establishes a collaborative strategy that aims to accelerate project timelines. We are grateful to be recognized as a valued Dalton partner by virtue of our unique capabilities.”

About Averica Discovery:
Founded in 2007, Averica Discovery is a Massachusetts-based analytical development contract research organization (CRO) with specialized expertise in small molecule analysis and purification. The company supports chemistry teams by providing material and information required to transition programs from drug discovery to development. With extensive experience in pharmaceutical R&D, it currently offers a variety of chromatography-based services, including method development and qualification, impurity isolation and identification, scalable small molecule purification, and custom assay development. For more information, please visit: http://www.avericadiscovery.com

About Dalton:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved and FDA registered GMP contract service provider of integrated chemistry, drug development and manufacturing services to the pharmaceutical and biotechnology industries. We bring 30 years of experience to our clients' projects and emphasize quality, speed and flexibility.

Dalton can accelerate your drug discovery and development program by integrating process development, API manufacturing and finish dose manufacturing all at a single location. Our full range of services in-house (drug discovery, flow chemistry, formulation and process development, analytical services, custom synthesis, cGMP sterile fill/finish, cGMP API manufacturing and/or dosage form manufacturing) all at one location enables us to be adaptable, flexible and cost-effective. To learn more about Dalton visit http://www.dalton.com

Our CMO 2016 Leadership Awards in the categories of Quality, Reliability, Capabilities, Expertise and Compatibility including “On-Time Delivery” and “Right First Time” from Life Science Leader reflect our ongoing commitment to our clients, peers and the business community.

For further information contact:
Peter Pekos
President & CEO
Dalton Pharma Services
416-661-2102

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peter Pekos
Dalton Pharma Services